Speaker(s): 

Madisyn Irace, PharmD, Clinical Pharmacist, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher DeFrancesco, PharmD, Clinical Pharmacist / Asst Pharmacy Residency Program Director Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe the pharmacology of beta blocker and calcium channel blocker toxicities ​

2. Assess signs, symptoms, and diagnostic results of the toxicities ​

3. Develop treatment recommendations and plans to address toxicities

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH; Anil Singh MD; Roop Parlapalli, MD, FHM, FACP; Carolyn Chilewshi, PA-C; Emilie Detweiler, PharmD, RPh; Alexa Kerecman, CRNP; John Sacino, CPhT, and Miranda Steigler, PharmD, RPh have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.